A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome.
Prenat Diagn
; 35(5): 440-6, 2015 May.
Article
in En
| MEDLINE
| ID: mdl-25273838
ABSTRACT
OBJECTIVE:
The aim of this article is to determine the cost effectiveness of cell free DNA (cfDNA) as a replacement for integrated screening using a societal cost perspective.METHOD:
This study used Monte-Carlo simulation with one-way and probabilistic sensitivity analysis.RESULTS:
Cell free DNA is more effective and less costly than integrated screening. The incremental cost-effectiveness ratio for cfDNA relative to the integrated test was -$277 955 per case detected (95th percent confidence interval -$881 882 to $532 785).CONCLUSION:
Cell free DNA screening is a cost-effective replacement for maternal serum screening when the lifetime costs of Down syndrome live births are considered. The adoption of cfDNA screening would save approximately $277 955 for each additional case detected over integrated screening.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prenatal Diagnosis
/
DNA
/
Abortion, Induced
/
Down Syndrome
Type of study:
Diagnostic_studies
/
Health_economic_evaluation
/
Screening_studies
Limits:
Female
/
Humans
/
Pregnancy
Language:
En
Journal:
Prenat Diagn
Year:
2015
Document type:
Article
Affiliation country:
United States